{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:48:59Z","timestamp":1764859739697,"version":"3.40.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Asan Medical Center","award":["2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1"],"award-info":[{"award-number":["2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1","2023IP0077-1"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798"],"award-info":[{"award-number":["No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798","No. 2023R1A2C2007798"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korea Health Technology R&D Project through the Korea Health Industry Development Institute","award":["HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198"],"award-info":[{"award-number":["HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198","HR21C0198"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95773-6","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T17:48:31Z","timestamp":1743788911000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct prognostic implications of blood neuronal and astroglial biomarkers in neuromyelitis optica spectrum disorders versus multiple sclerosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Wangyong","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eun-Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dayoung","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bum Joon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inhye","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynkyung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keonwoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Yon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee-Jae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyemi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunjin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"95773_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/ana.410360704","volume":"36 Suppl","author":"BG Weinshenker","year":"1994","unstructured":"Weinshenker, B. G. Natural history of multiple sclerosis. Ann. Neurol. 36 Suppl, 6\u201311. https:\/\/doi.org\/10.1002\/ana.410360704 (1994).","journal-title":"Ann. Neurol."},{"key":"95773_CR2","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/wnl.46.4.907","volume":"46","author":"FD Lublin","year":"1996","unstructured":"Lublin, F. D. & Reingold, S. C. Defining the clinical course of multiple sclerosis: results of an international survey. National multiple sclerosis society (USA) advisory committee on clinical trials of new agents in multiple sclerosis. Neurology 46, 907\u2013911. https:\/\/doi.org\/10.1212\/wnl.46.4.907 (1996).","journal-title":"Neurology"},{"key":"95773_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin, F. D. et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 83, 278\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000000560 (2014).","journal-title":"Neurology"},{"key":"95773_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","volume":"88","author":"I Kawachi","year":"2017","unstructured":"Kawachi, I. & Lassmann, H. Neurodegeneration in multiple sclerosis and neuromyelitis Optica. J. Neurol. Neurosurg. Psychiatry. 88, 137\u2013145. https:\/\/doi.org\/10.1136\/jnnp-2016-313300 (2017).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"95773_CR5","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/s0140-6736(04)17551-x","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon, V. A. et al. A serum autoantibody marker of neuromyelitis Optica: distinction from multiple sclerosis. Lancet 364, 2106\u20132112. https:\/\/doi.org\/10.1016\/s0140-6736(04)17551-x (2004).","journal-title":"Lancet"},{"key":"95773_CR6","doi-asserted-by":"publisher","unstructured":"Jarius, S. & Wildemann, B. The history of neuromyelitis Optica. J. Neuroinflammation. 10 https:\/\/doi.org\/10.1186\/1742-2094-10-8 (2013).","DOI":"10.1186\/1742-2094-10-8"},{"key":"95773_CR7","doi-asserted-by":"publisher","first-page":"21512","DOI":"10.1073\/pnas.2011249117","volume":"117","author":"S Kuerten","year":"2020","unstructured":"Kuerten, S. et al. Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. Proc. Natl. Acad. Sci. U S A. 117, 21512\u201321518. https:\/\/doi.org\/10.1073\/pnas.2011249117 (2020).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"95773_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41582-022-00700-2","volume":"18","author":"R Hoftberger","year":"2022","unstructured":"Hoftberger, R., Lassmann, H., Berger, T. & Reindl, M. Pathogenic autoantibodies in multiple sclerosis - from a simple Idea to a complex concept. Nat. Rev. Neurol. 18, 681\u2013688. https:\/\/doi.org\/10.1038\/s41582-022-00700-2 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"95773_CR9","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/s41591-024-02938-3","volume":"30","author":"CR Zamecnik","year":"2024","unstructured":"Zamecnik, C. R. et al. An autoantibody signature predictive for multiple sclerosis. Nat. Med. 30, 1300\u20131308. https:\/\/doi.org\/10.1038\/s41591-024-02938-3 (2024).","journal-title":"Nat. Med."},{"key":"95773_CR10","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/acn3.51070","volume":"7","author":"EJ Lee","year":"2020","unstructured":"Lee, E. J. et al. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases. Ann. Clin. Transl Neurol. 7, 992\u20131001. https:\/\/doi.org\/10.1002\/acn3.51070 (2020).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"95773_CR11","doi-asserted-by":"publisher","unstructured":"Kim, H. et al. Serum biomarkers in Myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol. Neuroimmunol. Neuroinflamm. 7 https:\/\/doi.org\/10.1212\/NXI.0000000000000708 (2020).","DOI":"10.1212\/NXI.0000000000000708"},{"key":"95773_CR12","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1038\/s41598-023-32748-5","volume":"13","author":"HJ Kim","year":"2023","unstructured":"Kim, H. J. et al. Serum proteins for monitoring and predicting visual function in patients with recent optic neuritis. Sci. Rep. 13, 5609. https:\/\/doi.org\/10.1038\/s41598-023-32748-5 (2023).","journal-title":"Sci. Rep."},{"key":"95773_CR13","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1038\/s41598-023-30755-0","volume":"13","author":"KW Kim","year":"2023","unstructured":"Kim, K. W. et al. Disease characteristics of idiopathic transverse myelitis with serum neuronal and astroglial damage biomarkers. Sci. Rep. 13, 3988. https:\/\/doi.org\/10.1038\/s41598-023-30755-0 (2023).","journal-title":"Sci. Rep."},{"key":"95773_CR14","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/WNL.0000000000003653","volume":"88","author":"J Kuhle","year":"2017","unstructured":"Kuhle, J. et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology 88, 826\u2013831. https:\/\/doi.org\/10.1212\/WNL.0000000000003653 (2017).","journal-title":"Neurology"},{"key":"95773_CR15","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1177\/13524585211047977","volume":"27","author":"T Uher","year":"2021","unstructured":"Uher, T. et al. Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. Mult Scler. 27, 2001\u20132013. https:\/\/doi.org\/10.1177\/13524585211047977 (2021).","journal-title":"Mult Scler."},{"key":"95773_CR16","doi-asserted-by":"publisher","unstructured":"Barro, C. et al. Serum GFAP and NfL levels differentiate subsequent progression and disease activity in patients with progressive multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 10 https:\/\/doi.org\/10.1212\/NXI.0000000000200052 (2023).","DOI":"10.1212\/NXI.0000000000200052"},{"key":"95773_CR17","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jamaneurol.2019.2137","volume":"76","author":"E Canto","year":"2019","unstructured":"Canto, E. et al. Association between serum neurofilament light chain levels and Long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol. 76, 1359\u20131366. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2137 (2019).","journal-title":"JAMA Neurol."},{"key":"95773_CR18","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1177\/1352458518782005","volume":"24","author":"A Bhan","year":"2018","unstructured":"Bhan, A. et al. Neurofilaments and 10-year follow-up in multiple sclerosis. Mult Scler. 24, 1301\u20131307. https:\/\/doi.org\/10.1177\/1352458518782005 (2018).","journal-title":"Mult Scler."},{"key":"95773_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","volume":"80","author":"S Meier","year":"2023","unstructured":"Meier, S. et al. Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis. JAMA Neurol. 80, 287\u2013297. https:\/\/doi.org\/10.1001\/jamaneurol.2022.5250 (2023).","journal-title":"JAMA Neurol."},{"key":"95773_CR20","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro, C. et al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141, 2382\u20132391. https:\/\/doi.org\/10.1093\/brain\/awy154 (2018).","journal-title":"Brain"},{"key":"95773_CR21","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","volume":"93","author":"M Watanabe","year":"2019","unstructured":"Watanabe, M. et al. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93, e1299\u2013e1311. https:\/\/doi.org\/10.1212\/WNL.0000000000008160 (2019).","journal-title":"Neurology"},{"key":"95773_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","volume":"89","author":"O Aktas","year":"2021","unstructured":"Aktas, O. et al. Serum glial fibrillary acidic protein: A neuromyelitis Optica spectrum disorder biomarker. Ann. Neurol. 89, 895\u2013910. https:\/\/doi.org\/10.1002\/ana.26067 (2021).","journal-title":"Ann. Neurol."},{"key":"95773_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","volume":"18","author":"P Schindler","year":"2021","unstructured":"Schindler, P. et al. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis Optica spectrum disorder. J. Neuroinflammation. 18, 105. https:\/\/doi.org\/10.1186\/s12974-021-02138-7 (2021).","journal-title":"J. Neuroinflammation"},{"key":"95773_CR24","doi-asserted-by":"publisher","first-page":"865730","DOI":"10.3389\/fneur.2022.865730","volume":"13","author":"H Kim","year":"2022","unstructured":"Kim, H., Lee, E. J., Lim, Y. M. & Kim, K. K. Glial fibrillary acidic protein in blood as a disease biomarker of neuromyelitis Optica spectrum disorders. Front. Neurol. 13, 865730. https:\/\/doi.org\/10.3389\/fneur.2022.865730 (2022).","journal-title":"Front. Neurol."},{"key":"95773_CR25","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/13524585211024978","volume":"28","author":"H Kim","year":"2022","unstructured":"Kim, H. et al. Longitudinal follow-up of serum biomarkers in patients with neuromyelitis Optica spectrum disorder. Mult Scler. 28, 512\u2013521. https:\/\/doi.org\/10.1177\/13524585211024978 (2022).","journal-title":"Mult Scler."},{"key":"95773_CR26","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/1744666X.2023.2148657","volume":"19","author":"P Schindler","year":"2023","unstructured":"Schindler, P. et al. Glial fibrillary acidic protein as a biomarker in neuromyelitis Optica spectrum disorder: a current review. Expert Rev. Clin. Immunol. 19, 71\u201391. https:\/\/doi.org\/10.1080\/1744666X.2023.2148657 (2023).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"95773_CR27","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto, G. et al. Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857\u2013870. https:\/\/doi.org\/10.1002\/ana.24954 (2017).","journal-title":"Ann. Neurol."},{"key":"95773_CR28","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1177\/1352458519885613","volume":"26","author":"J Kuhle","year":"2020","unstructured":"Kuhle, J. et al. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult Scler. 26, 1691\u20131699. https:\/\/doi.org\/10.1177\/1352458519885613 (2020).","journal-title":"Mult Scler."},{"key":"95773_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1212\/WNL.0000000000010346","volume":"95","author":"R Kapoor","year":"2020","unstructured":"Kapoor, R. et al. Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology 95, 436\u2013444. https:\/\/doi.org\/10.1212\/WNL.0000000000010346 (2020).","journal-title":"Neurology"},{"key":"95773_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert, P. et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 21, 246\u2013257. https:\/\/doi.org\/10.1016\/S1474-4422(22)00009-6 (2022).","journal-title":"Lancet Neurol."},{"key":"95773_CR31","doi-asserted-by":"publisher","first-page":"104970","DOI":"10.1016\/j.ebiom.2024.104970","volume":"101","author":"MS Freedman","year":"2024","unstructured":"Freedman, M. S. et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine 101, 104970. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104970 (2024).","journal-title":"EBioMedicine"},{"key":"95773_CR32","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1007\/s00415-024-12389-y","volume":"271","author":"I Rosenstein","year":"2024","unstructured":"Rosenstein, I. et al. Association of serum glial fibrillary acidic protein with progression independent of relapse activity in multiple sclerosis. J. Neurol. 271, 4412\u20134422. https:\/\/doi.org\/10.1007\/s00415-024-12389-y (2024).","journal-title":"J. Neurol."},{"key":"95773_CR33","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1001\/archneurol.2009.174","volume":"66","author":"M Calabrese","year":"2009","unstructured":"Calabrese, M. et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch. Neurol. 66, 1144\u20131150. https:\/\/doi.org\/10.1001\/archneurol.2009.174 (2009).","journal-title":"Arch. Neurol."},{"key":"95773_CR34","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1001\/jamaneurol.2022.1025","volume":"79","author":"A Cagol","year":"2022","unstructured":"Cagol, A. et al. Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol. 79, 682\u2013692. https:\/\/doi.org\/10.1001\/jamaneurol.2022.1025 (2022).","journal-title":"JAMA Neurol."},{"key":"95773_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/jnen\/nly121","volume":"78","author":"JW Prineas","year":"2019","unstructured":"Prineas, J. W. & Lee, S. Multiple sclerosis: destruction and regeneration of astrocytes in acute lesions. J. Neuropathol. Exp. Neurol. 78, 140\u2013156. https:\/\/doi.org\/10.1093\/jnen\/nly121 (2019).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"95773_CR36","doi-asserted-by":"publisher","first-page":"102810","DOI":"10.1016\/j.msard.2021.102810","volume":"50","author":"M Saraste","year":"2021","unstructured":"Saraste, M. et al. Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI. Mult Scler. Relat. Disord. 50, 102810. https:\/\/doi.org\/10.1016\/j.msard.2021.102810 (2021).","journal-title":"Mult Scler. Relat. Disord"},{"key":"95773_CR37","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1212\/WNL.0000000000012326","volume":"97","author":"P Maggi","year":"2021","unstructured":"Maggi, P. et al. Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis. Neurology 97, e543\u2013e553. https:\/\/doi.org\/10.1212\/WNL.0000000000012326 (2021).","journal-title":"Neurology"},{"key":"95773_CR38","doi-asserted-by":"publisher","first-page":"105093","DOI":"10.1016\/j.msard.2023.105093","volume":"80","author":"N Molazadeh","year":"2023","unstructured":"Molazadeh, N. et al. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis Optica spectrum disorder, Myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis. Mult Scler. Relat. Disord. 80, 105093. https:\/\/doi.org\/10.1016\/j.msard.2023.105093 (2023).","journal-title":"Mult Scler. Relat. Disord"},{"key":"95773_CR39","doi-asserted-by":"publisher","first-page":"e209940","DOI":"10.1212\/WNL.0000000000209940","volume":"103","author":"P Siriratnam","year":"2024","unstructured":"Siriratnam, P. et al. Prevalence of progression independent of relapse activity and relapse-Associated worsening in patients with AQP4-IgG-Positive NMOSD. Neurology 103, e209940. https:\/\/doi.org\/10.1212\/WNL.0000000000209940 (2024).","journal-title":"Neurology"},{"key":"95773_CR40","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1212\/WNL.0b013e318200d80c","volume":"75","author":"BF Popescu","year":"2010","unstructured":"Popescu, B. F. et al. Absence of cortical demyelination in neuromyelitis Optica. Neurology 75, 2103\u20132109. https:\/\/doi.org\/10.1212\/WNL.0b013e318200d80c (2010).","journal-title":"Neurology"},{"key":"95773_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ana.23721","volume":"73","author":"E Saji","year":"2013","unstructured":"Saji, E. et al. Cognitive impairment and cortical degeneration in neuromyelitis Optica. Ann. Neurol. 73, 65\u201376. https:\/\/doi.org\/10.1002\/ana.23721 (2013).","journal-title":"Ann. Neurol."},{"key":"95773_CR42","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00401-012-1009-1","volume":"124","author":"W Bruck","year":"2012","unstructured":"Bruck, W. et al. Reduced astrocytic NF-kappaB activation by Laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 124, 411\u2013424. https:\/\/doi.org\/10.1007\/s00401-012-1009-1 (2012).","journal-title":"Acta Neuropathol."},{"key":"95773_CR43","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/glia.22443","volume":"61","author":"CF Brosnan","year":"2013","unstructured":"Brosnan, C. F. & Raine, C. S. The astrocyte in multiple sclerosis revisited. Glia 61, 453\u2013465. https:\/\/doi.org\/10.1002\/glia.22443 (2013).","journal-title":"Glia"},{"key":"95773_CR44","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ana.24608","volume":"79","author":"M Hokari","year":"2016","unstructured":"Hokari, M. et al. Clinicopathological features in anterior visual pathway in neuromyelitis Optica. Ann. Neurol. 79, 605\u2013624. https:\/\/doi.org\/10.1002\/ana.24608 (2016).","journal-title":"Ann. Neurol."},{"key":"95773_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","volume":"68","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk, D. M., Pittock, S. J., Lucchinetti, C. F., Lennon, V. A. & Weinshenker, B. G. A secondary progressive clinical course is uncommon in neuromyelitis Optica. Neurology 68, 603\u2013605. https:\/\/doi.org\/10.1212\/01.wnl.0000254502.87233.9a (2007).","journal-title":"Neurology"},{"key":"95773_CR46","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J Muller","year":"2023","unstructured":"Muller, J. et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: A systematic review. JAMA Neurol. 80, 1232\u20131245. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3331 (2023).","journal-title":"JAMA Neurol."},{"key":"95773_CR47","doi-asserted-by":"publisher","first-page":"14649","DOI":"10.1038\/s41598-024-65486-3","volume":"14","author":"D Seo","year":"2024","unstructured":"Seo, D. et al. Digital symbol-digit modalities test with modified flexible protocols in patients with CNS demyelinating diseases. Sci. Rep. 14, 14649. https:\/\/doi.org\/10.1038\/s41598-024-65486-3 (2024).","journal-title":"Sci. Rep."},{"key":"95773_CR48","doi-asserted-by":"publisher","first-page":"104375","DOI":"10.1016\/j.msard.2022.104375","volume":"68","author":"TA Fuchs","year":"2022","unstructured":"Fuchs, T. A. et al. Repeated forms, testing intervals, and SDMT performance in a large multiple sclerosis dataset. Mult Scler. Relat. Disord. 68, 104375. https:\/\/doi.org\/10.1016\/j.msard.2022.104375 (2022).","journal-title":"Mult Scler. Relat. Disord"},{"key":"95773_CR49","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1212\/WNL.0000000000207301","volume":"101","author":"N Castrogiovanni","year":"2023","unstructured":"Castrogiovanni, N. et al. Longitudinal changes in cognitive test scores in patients with Relapsing-Remitting multiple sclerosis: an analysis of the DECIDE dataset. Neurology 101, e1\u2013e11. https:\/\/doi.org\/10.1212\/WNL.0000000000207301 (2023).","journal-title":"Neurology"},{"key":"95773_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk, D. M. et al. International consensus diagnostic criteria for neuromyelitis Optica spectrum disorders. Neurology 85, 177\u2013189. https:\/\/doi.org\/10.1212\/WNL.0000000000001729 (2015).","journal-title":"Neurology"},{"key":"95773_CR51","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson, A. J. et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17, 162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2 (2018).","journal-title":"Lancet Neurol."},{"key":"95773_CR52","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1177\/1352458516688955","volume":"23","author":"SM Rao","year":"2017","unstructured":"Rao, S. M. et al. Processing speed test: validation of a self-administered, iPad((R))-based tool for screening cognitive dysfunction in a clinic setting. Mult Scler. 23, 1929\u20131937. https:\/\/doi.org\/10.1177\/1352458516688955 (2017).","journal-title":"Mult Scler."},{"key":"95773_CR53","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1111\/ene.15406","volume":"29","author":"S Sharmin","year":"2022","unstructured":"Sharmin, S. et al. Confirmed disability progression as a marker of permanent disability in multiple sclerosis. Eur. J. Neurol. 29, 2321\u20132334. https:\/\/doi.org\/10.1111\/ene.15406 (2022).","journal-title":"Eur. J. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95773-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95773-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95773-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:55:43Z","timestamp":1744286143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95773-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95773"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95773-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"22 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Tables.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11326"}}